Answers are grounded in this paper and cite their sources.
Nipah virus (NiV) is a highly pathogenic zoonotic henipavirus that causes severe respiratory and neurological disease, yet no specific therapeutics are approved for human NiV infection. Because studies involving live NiV require biosafety level 4 containment and are technically demanding, computational host-directed drug repositioning provides a practical strategy for prioritizing candidates before experimental validation. Using the public NiV infection transcriptomic dataset GSE166707, we developed a time-resolved host-response drug-repositioning framework that integrated time-point differential expression analysis with time-series modeling. Core temporal genes were stratified into host dependency factors, host restriction factors and residual host-response genes using annotations from the Human–Virus Interaction DataBase. Candidate drugs were prioritized by combining Connectivity Map (CMap) reversal analysis, network proximity analysis, literature-curated NiV host-pathway directionality, pharmacological suitability and reported antiviral evidence. Suitable public drug-perturbation transcriptomic datasets were further analyzed by gene set enrichment analysis (GSEA) to evaluate their consistency with the predicted reversal directions. We identified 1116 genes differentially expressed at one or more time points and 1677 genes exhibiting significant temporal expression patterns, whose intersection defined a 516-gene core temporal host-response signature comprising 58 host dependency factors, 18 host restriction factors and 440 residual host-response genes. This signature captured a staged transition from early virus-associated recognition to inflammatory signaling, endoplasmic reticulum stress, increased protein-processing demands, and dysregulation of the cell cycle and DNA replication. Integrated screening yielded 38 candidate drugs, from which metformin, fenofibrate, lonafarnib and probenecid were prioritized as host-directed candidates warranting further experimental validation. Gene-level reversal and host-network analyses revealed drug-specific modulation of NiV-associated host programs, while external drug-perturbation GSEA supported selected host-factor reversal patterns for metformin and fenofibrate. Overall, this framework provides a reproducible strategy for prioritizing host-directed therapeutic candidates against NiV infection.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: